Paul Harker-Murray
Overview
Explore the profile of Paul Harker-Murray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daw S, Cole P, Hoppe B, Hodgson D, Beishuizen A, Garnier N, et al.
JAMA Oncol
. 2025 Jan;
PMID: 39745739
Importance: Retrieval strategies for children, adolescents, and young adults with relapsed classic Hodgkin lymphoma (cHL) aim to maintain efficacy while minimizing long-term toxic effects. Children, adolescents, and young adults with...
2.
Hayashi R, Hermiston M, Wood B, Teachey D, Devidas M, Chen Z, et al.
Blood
. 2024 Mar;
143(20):2053-2058.
PMID: 38457359
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children's Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or...
3.
Alexander S, Harker-Murray P, Hayashi R
Front Immunol
. 2024 Mar;
15:1379278.
PMID: 38449864
No abstract available.
4.
Castellino S, Giulino-Roth L, Harker-Murray P, Kahn J, Forlenza C, Cho S, et al.
Pediatr Blood Cancer
. 2023 Jul;
70 Suppl 6:e30580.
PMID: 37505794
The goal of therapy in pediatric Hodgkin lymphoma (HL) is to maximize overall survival while minimizing the morbidity of curative therapy. Key findings from recent Children's Oncology Group (COG) trials...
5.
Harker-Murray P, Mauz-Korholz C, Leblanc T, Mascarin M, Michel G, Cooper S, et al.
Blood
. 2022 Dec;
141(17):2075-2084.
PMID: 36564047
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous hematopoietic cell transplantation (auto-HCT) have poor survival outcomes. CheckMate 744,...
6.
Teachey D, Devidas M, Wood B, Chen Z, Hayashi R, Hermiston M, et al.
J Clin Oncol
. 2022 Mar;
40(19):2106-2118.
PMID: 35271306
Purpose: To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III...
7.
Scheuermann A, Moskop A, Hopp A, Bone K, Drendel H, Talano J, et al.
J Pediatr Hematol Oncol
. 2022 Mar;
44(5):268-270.
PMID: 35235548
Donor cell leukemia is a rare complication following hematopoietic stem cell transplant (HSCT). There are currently few reports in children and only rare, reported cases of donor-derived myelodysplastic syndrome/acute myeloid...
8.
Scheuermann A, Harker-Murray P, Pommert L
J Pediatr Hematol Oncol
. 2021 Dec;
44(3):e709-e712.
PMID: 34966101
Asparaginase, a critical component of current pediatric acute leukemia treatment protocols, is associated with a number of serious side effects, one of which is pancreatitis. Pancreatitis can result in significant...
9.
Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, et al.
Leukemia
. 2021 May;
35(10):2994-2997.
PMID: 33941850
No abstract available.
10.
Esbenshade A, Kahalley L, Baertschiger R, Dasgupta R, Goldsmith K, Nathan P, et al.
Pediatr Blood Cancer
. 2019 Jul;
66(10):e27920.
PMID: 31309744
Background: Identification and development of young investigators (YI) is critical to the long-term success of research organizations. In 2004, the Children's Oncology Group (COG) created a mentorship program to foster...